Focused Clinical Training
GLP-1 Microdosing Protocols
Beyond standard titration and beyond primary weight loss. This is GLP-1 therapy applied with clinical intention.
Clinical Application One
Your patient discontinues GLP-1 therapy at week eight. Not because it was not working. Because the protocol failed them.
Standard GLP-1 titration schedules were designed for the average patient in a phase three clinical trial. A meaningful proportion of patients discontinue within eight to twelve weeks, not because GLP-1 therapy was wrong for them, but because the delivery protocol did not account for individual neurobiological variability, GI sensitivity, or clinical goals that do not require maximum dose to achieve.
Microdosing in this context means initiating at sub-standard doses for longer, stabilizing at the minimum effective dose, or modifying frequency to maximize tolerability and sustained adherence. The goal is the same as any GLP-1 protocol. The approach is matched to the patient in front of you.
The best dose is the one the patient takes consistently.
Clinical Application Two
GLP-1 therapy is not only a weight loss tool. For a growing patient population it is a metabolic optimization strategy.
You are seeing patients who do not meet criteria for obesity treatment but who present with mild insulin resistance affecting energy and body composition, chronic low-grade inflammation driving systemic symptoms, hormonal dysregulation that is not responding to standard interventions, or metabolic inefficiency that persists despite appropriate lifestyle habits. These patients are not GLP-1 candidates under conventional prescribing criteria. Under a microdosing framework they may be exactly the right candidate.
What this approach targets
| Insulin sensitivity and metabolic flexibility in patients without primary obesity diagnosis | |
| Chronic low-grade systemic inflammation as a driver of hormonal and metabolic dysfunction | |
| Mitochondrial function and sustained energy production | |
| Long-term metabolic health and disease prevention as a clinical endpoint |
Appropriate patient profile for this application
| Mild insulin resistance with energy fluctuation, body composition challenges, or inflammatory burden | |
| Patients seeking metabolic optimization alongside hormone therapy or integrative protocols | |
| Those with metabolic inefficiency that persists despite appropriate nutrition and exercise | |
| Not appropriate for Type 1 diabetes, uncontrolled Type 2 diabetes, history of medullary thyroid cancer, MEN-2 syndrome, or severe GI disorders |
This course covers both clinical applications. The prescribing framework, documentation standards, patient selection criteria, and scope of practice guidance apply across both. You leave with the clinical reasoning to identify which approach is appropriate for each patient and how to implement and document it with confidence.
What You Will Learn
Four modules. Twelve lessons. One complete clinical framework.
01
A Precision Prescribing Approach
The neurobiological basis for variable GLP-1 response. What microdosing is and is not. Patient selection using a five-category candidacy framework covering both tolerability and metabolic optimization applications. How to define the clinical goal across three distinct clinical applications before writing the prescription.
02
Prescribing and Titration in Practice
Eight-week hold protocols for semaglutide and tirzepatide. Extended maintenance microdose strategies. Every-other-week frequency modification with pharmacokinetic rationale. Combining microdosing with the three-prescription lifestyle system including hormone optimization and targeted supplementation.
03
Side Effects and Response Monitoring
Prevention-first model with four written protocols before first injection. The GI-sensitive escalation ladder. Three-question dose decision framework for advancing, holding, or stepping down. Long-term sustainability, cost management, and planned drug holidays.
04
Documentation and Clinical Integration
Six required documentation elements for modified protocol prescribing. ICD-10 coding reference. NP scope of practice for compounded, frequency-modified, and metabolic optimization prescribing. Building microdosing into your practice workflow including telehealth.
What Is Included
Everything you need to implement immediately.
$297
One-time enrollment. Lifetime access.
Contact hours being prepared for ANCC/CNA submission. The Colorado Nurses Association is accredited as an approver of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Questions Before Enrolling
Book a free Bridge Call.
Tell Dr. Erwin where you are in your GLP-1 prescribing practice and what you are trying to solve. You will get an honest answer about whether this course is the right fit for you.
Book Your Bridge Call
Join Our Free Trial
Get started today before this once in a lifetime opportunity expires.